Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 9/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.47 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675773 | 0.95 | FKBP1A (0.46) | FKBP1AABCC1FKBP4FKBP5PTAFR | |
| SCHEMBL8462850 | 0.86 | FKBP1A (0.40) | FKBP1AABCC1FKBP4FKBP5PTAFR | |
| SCHEMBL6473445 | 0.81 | TBXAS1 (0.39) | FKBP1ALMNAKDM4EALDH1A1POLB | |
| SCHEMBL6476183 | 0.81 | TBXAS1 (0.41) | FKBP1AKDM4EALDH1A1POLBHPGD | |
| SCHEMBL3673587 | 0.72 | FKBP1A (0.76) | FKBP1AABCC1FKBP4FKBP5 | |
| SCHEMBL3673585 | 0.72 | FKBP1A (0.76) | FKBP1AABCC1FKBP4FKBP5 | |
| SCHEMBL5015211 | 0.71 | FKBP1A (0.48) | FKBP1AABCC1FKBP4FKBP5PTAFR | |
| SCHEMBL7464552 | 0.67 | FKBP1A (0.47) | FKBP1AABCC1FKBP4FKBP5PTAFR | |
| SCHEMBL5015213 | 0.66 | FKBP1A (0.45) | FKBP1AABCC1FKBP4FKBP5LMNA | |
| SCHEMBL7129468 | 0.66 | FKBP1A (1.00) | FKBP1AABCC1FKBP4FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1138673-B1 | Novel carbamates and ureas as modifiers of multi-drug resistance | VERTEX PHARMA (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1666053-A1 | Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors | Vertex Pharmceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1138673-A2 | Novel carbamates and ureas as modifiers of multi-drug resistance | Vertex Pharmaceuticals Incorporated (US) | 2001-10-04 | — | — | EP | claimed |
| EP-0941113-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | Vertex Pharmaceuticals Incorporated (US) | 1999-09-15 | — | — | EP | claimed |
| WO-1998020893-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-05-22 | — | — | WO | claimed |
| EP-0754176-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | Vertex Pharmaceuticals Incorporated (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026337-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-10-05 | — | — | WO | claimed |
| US-7825136-B2 | Potentiators of antibacterial activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090291964-A1 | Potentiators of Antibacterial Activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-26 | — | — | US | disclosed |
| EP-1138673-B1 | Novel carbamates and ureas as modifiers of multi-drug resistance | VERTEX PHARMA (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| WO-2005007162-A1 | COMPOUNDS AUGMENTING THE ACTIVITY OF ANTIBACTERIAL AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
| US-5744485-A | INCREASE SENSITIVITY OF CELLS; CANCER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291964-A1 | Potentiators of Antibacterial Activity | SLC11A2, MPO, ABCB11 | FKBP1A 1960/4885ABCC1 72/4885FKBP4 2416/4885 |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | TLR1, ABCB11, SLC7A1 | FKBP1A 2885/4885ABCC1 14/4885FKBP4 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.